Sees 2022 Dojolvi revenue $55M-$56M. Sees 2022 total Crysvita revenue $277M-$279M. Sees 2022 Crysvita in Ultragenyx Territories revenue $257M-$258M. "We have made substantial investments in our pipeline and manufacturing capabilities over the last two years that put us in a special position to advance multiple transformative treatments in late-stage development while continuing to drive revenue growth, delivering approved medicines globally for rare disease patients," said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. "We have also made a substantial effort to focus on key value drivers within the pipeline and reduce cash spending to maintain our strong financial position through 2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
- Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Ultragenyx assumed with a Buy at H.C. Wainwright
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Present at Piper Sandler Healthcare Conference
